(Q42547184)

2 November 2017

title

Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group (English)

1 reference

2 November 2017

0 references

1 reference

J N Cohn

1

1 reference

2 November 2017

M B Fowler

2

1 reference

2 November 2017

M R Bristow

3

1 reference

2 November 2017

W S Colucci

4

1 reference

2 November 2017

E M Gilbert

5

1 reference

2 November 2017

V Kinhal

6

1 reference

2 November 2017

S K Krueger

7

1 reference

2 November 2017

T Lejemtel

8

1 reference

2 November 2017

K A Narahara

9

1 reference

2 November 2017

M Packer

10

1 reference

2 November 2017

S T Young

11

1 reference

2 November 2017

T L Holcslaw

12

1 reference

2 November 2017

M A Lukas

13

1 reference

2 November 2017

language of work or name

1 reference

1 September 1997

1 reference

Journal of Cardiac Failure

2 November 2017

published in

1 reference

2 November 2017

volume

3

1 reference

2 November 2017

issue

3

1 reference

2 November 2017

page(s)

173-179

1 reference

Hemodynamic assessment of amrinone. A new inotropic agent

2 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

Pirbuterol: a new oral sympathomimetic amine for the treatment of congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

Beneficial effects of long-term beta-blockade in congestive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

Double-Blind, Placebo-Controlled Study of the Long-term Efficacy of Carvedilol in Patients With Severe Chronic Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990013-0

7 January 2021

10.1016/S1071-9164(97)90013-0

Identifiers

DOI

1 reference

2 November 2017

1 reference